CRISPR Therapeutics rose in premarket trading after J.P. Morgan initiated coverage with an Overweight rating and a $70 price target.

#CRSP #CRSPStock #CRISPRTherapeutics #CRSPNews #CRSPStockNews #CRISPRTherapeuticsStock #CRISPRTherapeuticsNews #CRISPRTherapeuticsStockNews #GeneEditing #Biotech
CRSP